Aptalis/Allerga Patent-Cliff Exposure & CMS Drug Spending Portfolio
Aptalis/Allerga (US): 4 reconciled FDA prescription therapies, $4.2M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 4 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $4.2M |
| 2024 Medicare Part D Spend | $2.2M |
| 2024 Medicaid Spend | $2.0M |
| California HCAI SB 17 Filings | 0 statutory filings in 2023 to 2026 panel |